Statement: IMC responds to Health Canada’s Interim Order Respecting Drug Shortages

Media Enquiries

Join media list

Press Release

Ottawa, December 2, 2020 – The following statement can be attributed to Declan Hamill, Vice President, Legal, Regulatory Affairs & Compliance, Innovative Medicines Canada in response to the Interim Order Respecting Drug Shortages issued by Health Canada.

“While we are still reviewing Health Canada’s Interim Order, Innovative Medicines Canada is supportive of the Government of Canada taking measures to help safeguard the supply of medicines intended for Canadian patients from being distributed for consumption outside of Canada.

“Canada cannot supply medicines and vaccines to the United States – a market ten times larger than its own population – without creating shortages and exposing Canadian patients to risk.

“Innovative Medicines Canada will continue to work collaboratively with the Government of Canada and other stakeholders to ensure that Canadian patients continue to have access to the medicines and vaccines that they need.”

About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

– 30 –

For further information:

Sarah Dion-Marquis
Director, Media and Public Relations
Telephone: 613-769-6510


Discover. Learn.

Informative content to keep you up to date on the most pressing issues facing our industry.